Polaris Stays Disciplined For Breakthroughs: An Interview With Alan Crane
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.
You may also be interested in...
Polaris’ focus on people and platforms was never more evident than in 2013, when it leveraged its relationship with one entrepreneur in particular to great effect.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.